Search research articles
Contact Us
Filters
Showing results (111-120 of 134) with videos related to
Page
of 14
Sort By:
Cancer Discovery
|
February 23, 2024
Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Eric Y Stutheit-Zhao, Enrique Sanz-Garcia, Zhihui Amy Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b Results
Ezra Y Rosen, Timothy A Yap, Elisa Fontana, et al.
JAMA Oncology
|
November 18, 2017
Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma
Stephanie Lheureux, Marcus O Butler, Blaise Clarke, et al.
Journal for Immunotherapy of Cancer
|
August 6, 2020
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
Kirsty Taylor, Helen Loo Yau, Ankur Chakravarthy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
Jung-Min Lee, Mark F Brady, Austin Miller, et al.
Nature Medicine
|
June 5, 2023
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
Timothy A Yap, Elisa Fontana, Elizabeth K Lee, et al.
Cancer Research Communications
|
March 6, 2023
Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
Stefano Marastoni, Ainhoa Madariaga, Aleksandra Pesic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2024
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
Christian Marth, Richard G Moore, Mariusz Bidziński, et al.
Journal for Immunotherapy of Cancer
|
March 15, 2022
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
Stephanie Lheureux, Daniela E Matei, Panagiotis A Konstantinopoulos, et al.
Nature Cancer
|
February 5, 2022
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Scott V Bratman, S Y Cindy Yang, Marco A J Iafolla, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 134) with videos related to
Sort By:
Page
of 14
Cancer Discovery
|
February 23, 2024
Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Eric Y Stutheit-Zhao, Enrique Sanz-Garcia, Zhihui Amy Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b Results
Ezra Y Rosen, Timothy A Yap, Elisa Fontana, et al.
JAMA Oncology
|
November 18, 2017
Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma
Stephanie Lheureux, Marcus O Butler, Blaise Clarke, et al.
Journal for Immunotherapy of Cancer
|
August 6, 2020
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
Kirsty Taylor, Helen Loo Yau, Ankur Chakravarthy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
Jung-Min Lee, Mark F Brady, Austin Miller, et al.
Nature Medicine
|
June 5, 2023
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
Timothy A Yap, Elisa Fontana, Elizabeth K Lee, et al.
Cancer Research Communications
|
March 6, 2023
Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer
Stefano Marastoni, Ainhoa Madariaga, Aleksandra Pesic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2024
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
Christian Marth, Richard G Moore, Mariusz Bidziński, et al.
Journal for Immunotherapy of Cancer
|
March 15, 2022
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
Stephanie Lheureux, Daniela E Matei, Panagiotis A Konstantinopoulos, et al.
Nature Cancer
|
February 5, 2022
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Scott V Bratman, S Y Cindy Yang, Marco A J Iafolla, et al.
Page
of 14